Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.